Interleukin 22, a Potential Therapeutic Target for Rheumatoid Arthritis

QIANG XIE, SHI-CUN WANG and JUN LI

J Rheumatol 2012;39;2220-2221
http://www.jrheum.org/content/39/11/2220

1. Sign up for TOCs and other alerts
   http://www.jrheum.org/alerts

2. Information on Subscriptions
   http://jrheum.com/faq

3. Information on permissions/orders of reprints
   http://jrheum.com/reprints_permissions

*The Journal of Rheumatology* is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.
Interleukin 22, a Potential Therapeutic Target for Rheumatoid Arthritis

To the Editor:

A recent report by Da Rocha, et al indicated that levels of interleukin 22 (IL-22) were increased in patients with rheumatoid arthritis (RA) compared with controls; levels of IL-22 correlated with Disease Activity Score (DAS28) and Clinical Disease Activity Index measures, rheumatoid factor positivity was correlated with higher levels of IL-22 in patients with RA, and the presence of bone erosions was associated with high IL-22 levels5. These findings suggest that IL-22 may be a good biomarker for assessment of activity in RA, and IL-22 seems to be a potential therapeutic target for RA.

Other studies have indicated the similar relationship between IL-22 and RA, where serum IL-22 levels were found to be increased in patients with RA compared with controls2,3,4, and high IL-22 levels correlated with bone erosions5. The IL-22 concentration in synovial fluid was higher in patients with RA compared with control2,3. In patients with RA, Th17 cells were recognized to produce higher IL-224. Th22 cells also produced IL-22 and the expression of Th22 cells. IL-22 were significantly elevated in RA patients5,6. More importantly, Th17/22 cells showed positive correlations with IL-22, C-reactive protein, and DAS28 data6. In addition, natural killer (NK)-22 cells in vitro can secrete higher levels of IL-22 and tumor necrosis factor-α (TNF-α), and NK-22 supernatant can induce the proliferation of RA fibroblast-like synoviocytes (FLS); however, addition of IL-22 antibody plus TNF-α antibody inhibited the proliferation of FLS induced by the NK-22 supernatant1. In vitro, human recombinant IL-22 (rhIL-22) significantly increased proliferation of RA synovial fluid and FLS and production of monocyte chemotactic protein-1, but an inhibitory effect of anti-IL-22R antibody on proliferation of FLS induced by rhIL-22 was found in RA1. Moreover, an experimental arthritis model (IL-1Ra−/−) displayed a progressive erosive arthritis characterized by upregulation of IL-22 in severely inflamed synovia; and anti-IL-22 treatment of IL-1Ra−/− mice significantly reduced the inflammation and bone erosions5. Similarly, in studies of collagen-induced arthritis (CIA), serum IL-22 levels were increased, and the specific IL-22RII was expressed in lymphoid tissue, including splenocytes. IL-22−/− mice were less susceptible to CIA than wild-type mice, as shown by their reduced incidence of arthritis and decreased pannus formation. Remarkably, the less severe form of arthritis in IL-22−/− mice was associated with increased production of collagen II-specific and total IgG antibodies. In vitro, IL-22 was found to promote osteoclastogenesis, a process that may contribute to its proinflammatory activity in CIA10. On the other hand, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) prevented corticosteroid-induced osteoporosis in patients with early RA, where 1,25(OH)2D3 directly modulated human Th17 polarization, accompanied by suppression of IL-17, TNF-α, and IL-22 production11. In patients with RA, rituximab reduced expression of IL-22 and Th17-positive cells in synovial tissue, and this correlated with better clinical outcomes. In vitro, rituximab strongly reduced IL-17 and IL-22 production induced by Candida albicans12.

These findings suggest therapeutic potential for patients with RA, and suggest a role for IL-22 in development of RA. Further studies are needed to clarify the role of IL-22 in RA. Therapeutic agents targeting IL-22 might result in innovative new therapies for RA.